Thin Layer Chromatography TLC

Laboratory Info Biotechnology

Thin Layer Chromatography (TLC) – Principle, Procedure, Diagram, and Applications

By Achuth B S
18 February 2024

thin layer chromatography

Thin Layer Chromatography is a chromatographic method for identifying and separating components from mixtures.

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

Regulatory Approval Healthcare & Pharmaceuticals News

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

18 July 202617 July 2026

Regulatory Intelligence Desk

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

Regulatory Approval Healthcare & Pharmaceuticals News

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

17 July 202617 July 2026

Regulatory Intelligence Desk

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Merger & Acquisitions Business Healthcare & Pharmaceuticals

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

16 July 202616 July 2026

BiotechReality Business Intelligence Desk

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

15 July 202616 July 2026

BiotechReality Business Intelligence Desk

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

Regulatory Approval Healthcare & Pharmaceuticals News Oncology

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

15 July 202615 July 2026

Regulatory Intelligence Desk

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

Merger & Acquisitions Healthcare & Pharmaceuticals News Oncology

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement

14 July 202615 July 2026

BiotechReality Business Intelligence Desk